scholarly journals Evaluation of the effectiveness and acceptability of intramuscular clozapine injection: illustrative case series

2020 ◽  
Vol 44 (6) ◽  
pp. 239-243 ◽  
Author(s):  
Rebecca Henry ◽  
Ruth Massey ◽  
Kathy Morgan ◽  
Johanne Deeks ◽  
Hannah Macfarlane ◽  
...  
Keyword(s):  
Side Effects ◽  
Case Series ◽  
Oral Route ◽  
Clinical Implications ◽  
Illustrative Case ◽  
Injection Site Pain ◽  
Efficacy And Safety ◽  
Clinical Presentations ◽  
The Uk ◽  
Site Pain

Aims and methodA series of eleven patients prescribed intramuscular clozapine at five UK sites is presented. Using routinely collected clinical data, we describe the use, efficacy and safety of this treatment modality.ResultsWe administered 188 doses of intramuscular clozapine to eight patients. The remaining three patients accepted oral medication. With the exception of minor injection site pain and nodules, side-effects were as expected with oral clozapine, and there were no serious untoward events. Nine patients were successfully established on oral clozapine with significant improvement in their clinical presentations.Clinical implicationsAlthough a novel formulation in the UK, we have shown that intramuscular clozapine can be used safely and effectively when the oral route is initially refused.

scholarly journals 167 Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil with 1-Day Initiation in Acutely Ill Patients with Schizophrenia

CNS Spectrums ◽  
2020 ◽  
Vol 25 (2) ◽  
pp. 306-307
Author(s):  
Peter J. Weiden ◽  
Amy Claxton ◽  
Yangchun Du ◽  
Sergey Yagoda ◽  
David Walling ◽  
...  
Keyword(s):  
Adverse Events ◽  
Outpatient Setting ◽  
Controlled Study ◽  
Injection Site Pain ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Secondary Analyses ◽  
Site Pain ◽  
Over Time ◽  
Funding Acknowledgements

Abstract:Objective:Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia.Methods:In the phase 3b double-blind ALPINE study, adults with schizophrenia were randomized to AL (AL NanoCrystal® Dispersion + oral aripiprazole 30 mg day 1; AL 1064 mg day 8 and every 8 weeks) or paliperidone palmitate (PP 234 mg day 1; PP 156 mg day 8 and every 4 weeks). Patients were discharged after 2 weeks of hospitalization and followed through week 25. Primary endpoint was within-group changes in PANSS total score from baseline to week 4 (observed cases). Secondary analyses included within-group changes at weeks 9 and 25 (observed) and between-group comparisons at weeks 4, 9, and 25 (MMRM). Adverse events (AEs) were monitored throughout the study.Results:200 patients were randomized (AL, n=99; PP, n=101); 56.6% and 42.6%, respectively, completed the study. Within-group changes from baseline in PANSS were −17.4 for AL and −20.1 for PP at week 4 (both groups, P<0.001) and continued to decline at weeks 9 (AL, −19.8; PP, −22.5) and 25 (AL, −23.3; PP, −21.7). The change in PANSS over time was similar between groups. AEs occurring in ≥10% of patients in either group were injection site pain (AL, 17.2%; PP, 24.8%), akathisia (AL, 9.1%; PP, 10.9%), and weight increased (AL, 9.1%; PP, 16.8%).Conclusions:AL and PP were effective and well-tolerated for initiating treatment of schizophrenia in the hospital and continuing in the outpatient setting.Funding Acknowledgements:This study was funded by Alkermes, Inc.

scholarly journals Immunogenicity and Safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CoV) in patients with malignancy

2021 ◽  
Author(s):  
Mona Ariamanesh ◽  
Pejman Porouhan ◽  
Babak PeyroShabany ◽  
Danial Fazilat-Panah ◽  
Mansoureh Dehghani ◽  
...  
Keyword(s):  
Side Effects ◽  
Hematological Malignancies ◽  
Neutralizing Antibody ◽  
Protein S ◽  
Immunological Methods ◽  
Injection Site Pain ◽  
Short Term ◽  
Patients With Cancer ◽  
Systemic Side Effects ◽  
Site Pain

Objective: Patients with malignancy suffer from a compromised immune system due to either the effects of malignancies or treatments. Cancer patients are at higher risk of different infections particularly SARS-CoV2 and usually produce weaker response to vaccines. The aim of this study was to evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine (Sinopharm, BBIBP-CoV) in patients with malignancy. Material and Method: In total 364 patients with cancer (median age: 54 years old, F/M ratio: 217/147) who received two doses of Sinopharm vaccine were enrolled in this study. Vaccine related side effects was assessed by a questionnaire and the presence of SARS-CoV-2 anti-Spike protein (S) IgG and neutralizing antibody two months following vaccination were measured by immunological methods. Results: Injection site pain and fever were the most common local and systemic side effects in vaccine receivers. Two months after the first dose, anti-S IgG and neutralizing antibody were detectable in 77.1% and 80.7% of all participants, respectively with an overall response to either or both measured in 86.9% of patients The rate of seroconversion was lower in older age, those with hematological malignancies and chemotherapy receivers. Conclusion: The result of study confirmed the safety and short-term efficacy of Sinopharm inactivated vaccine (BBIBP-CorV) in patients with different type of malignancies.

COVID-19 Vaccine and Fitness to Fly

2021 ◽  
Vol 92 (9) ◽  
pp. 698-701
Author(s):  
Daniel Gabbai ◽  
Aya Ekshtein ◽  
Omer Tehori ◽  
Oded Ben-Ari ◽  
Shachar Shapira
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Air Force ◽  
Side Effect ◽  
Common Side Effect ◽  
Injection Site Pain ◽  
Dose Administration ◽  
The Difference ◽  
Site Pain ◽  
The U.S

INTRODUCTION: On December 2020 the U.S. Food and Drug Administration (FDA) authorized the emergency use of Pfizer-BioNTech COVID-19 vaccine. This new vaccine has several side effects that can potentially impair function, which warrants special attention regarding aircrews fitness to fly following vaccination.METHODS: A survey was conducted in the Israeli Air Force (IAF) Aeromedical Center in order to characterize the side effects and their duration following Pfizer-BioNTech COVID-19 vaccine administration to aviators.RESULTS: The most common side effect was injection site pain. Headache, chills, myalgia, fatigue, and weakness were more common following the second dose administration. The difference is statistically significant. Following the second vaccine, duration of side effects was longer compared to the first vaccine (P-value 0.002).CONCLUSION: The IAF Aeromedical center policy for Pfizer-BioNTech COVID-19 vaccine recipients among aircrew members, based on side effects duration and severity, is to temporarily ground from flight duties for 24 and 48 h following the first and the second dose, respectively.Gabbai D, Ekshtein A, Tehori O, Ben-Ari O, Shapira S. COVID-19 vaccine and fitness to fly. Aerosp Med Hum Perform. 2021; 92(9):698701.

Aseptic myonecrosis following intramuscular benzathine penicllin G injection: a novel syndrome

Diagnosis ◽  
2017 ◽  
Vol 4 (1) ◽  
pp. 51-54 ◽  
Author(s):  
Nicholas Ryan ◽  
Andrew Olson
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Pediatric Patient ◽  
Similar Case ◽  
Streptococcal Pharyngitis ◽  
Penicillin G ◽  
Injection Site Pain ◽  
Benzathine Penicillin ◽  
Benzathine Penicillin G ◽  
Site Pain

AbstractWe report a novel syndrome of aseptic myonecrosis in a child occurring after intramuscular (IM) benzathine penicillin G injection for the treatment of streptococcal pharyngitis. Common side effects of IM injection, including transient injection site pain and inflammation, are common and well described. However, isolated myonecrosis following IM injection in the pediatric patient has not been previously reported. Only one similar case, following IM diclofenac injection, has been discussed in the adult literature.

Risperidone in the Treatment of Delusions of Infestation

1997 ◽  
Vol 27 (4) ◽  
pp. 403-409 ◽  
Author(s):  
Ovidio A. De Leóan ◽  
Kevin M. Furmaga ◽  
Andrea L. Canterbury ◽  
La Genia Bailey
Keyword(s):  
Side Effects ◽  
Case Series ◽  
Therapeutic Benefit ◽  
Extrapyramidal Side Effects ◽  
Efficacy And Safety ◽  
Safe Treatment

Objective: The aim of this study is to describe the efficacy and safety of risperidone, in the treatment of delusions of infestation. Method: The authors present a three-case series in which risperidone was used to treat delusions of infestation. Results: All three patients responded to risperidone and experienced no extrapyramidal side effects. Two of our patients had failed treatment with haloperidol and another had failed treatment with pimozide. Conclusions: Risperidone was an effective and safe treatment in three cases of delusions of infestation. It is possible that 5-HT2 antagonism is essential for therapeutic benefit in this condition.

scholarly journals Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination

2021 ◽  
Author(s):  
Balsam Qubais ◽  
Rula Al-Shahrabi ◽  
Shaikha Salah Alhaj ◽  
Zainab Mansour Alkokhardi ◽  
Ahmed Omar Adrees
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Demographic Data ◽  
Survey Study ◽  
Vaccine Hesitancy ◽  
Injection Site Pain ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Vaccination Site ◽  
Site Pain

Objectives Vaccines are one of the best interventions developed for eradicating COVID-19 the rapid creation of vaccinations was increased the risk of vaccine safety problems. The aim of this study to provide evidence on Sinopharm COVID-19 vaccine side effects. Methods A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of COVID-19 vaccine among individuals in the UAE. Demographic data chronic conditions side effects of the 1st and 2nd dose toward the vaccination, and the response of unwilling taking COVID-19 vaccine were reported. Results The most common side effects of post 1st dose (less than 49 years old vs >49 years) were normal injection site pain, fatigue, and headache while pain at the vaccination site fatigue lethargy headache and tenderness were the most side effects of the post 2nd dose in both groups. All the side effects in both doses were more prevalent among the participants less than 49-year-old group. Among females vs males side effects were more common in females compared with males in both doses in both doses. The most common adverse reactions of 1st dose in (females vs males) were fatigue lethargy headache while in 2nd dose were fatigue sever injection site pain. The most common reason of not willing to take the COVID-19 vaccine were the vaccines are not effective and they were not authorized to take vaccine. Conclusion The 1st and 2nd dose post-vaccination side effects were mild predictable and there were no hospitalization cases this data will help to reduce the vaccine hesitancy.

scholarly journals Surely you take complementary and alternative medicines?

2004 ◽  
Vol 28 (2) ◽  
pp. 36-39 ◽  
Author(s):  
Traolach Brugha ◽  
Hagen Rampes ◽  
Rachel Jenkins
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Complementary And Alternative Medicines ◽  
Substantial Growth ◽  
Alternative Medicines ◽  
Clinical Presentations ◽  
The Usa ◽  
The Subject ◽  
The Uk ◽  
Complementary And Alternative

A substantial proportion of our patients use or consider using complementary and alternative medicines (CAM) and other coping strategies. It is important that we acknowledge this, know something about the subject and are aware of current or potential developments in the field. These remedies might be harmless, beneficial or harmful and their side-effects might alter and confuse clinical presentations. We need to be vigilant of the potential for significant drug interactions between complementary and orthodox treatments. There is a substantial growth in complementary and alternative medical research in the USA, now beginning to follow in the UK. This will hopefully bring useful future progress.

Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series

2021 ◽  
Vol 18 ◽  
Author(s):  
Rakhmad Hidayat ◽  
Dinda Diafiri ◽  
Ramdinal Aviesena Zairinal ◽  
Ghafur Rasyid Arifin ◽  
Faiza Azzahroh ◽  
...  
Keyword(s):  
Adverse Events ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Case Series ◽  
Mortality Rates ◽  
High Morbidity ◽  
Injection Site Pain ◽  
Stroke Incidence ◽  
Virus Spreading ◽  
Site Pain

Background: Coronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021. A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most adverse events following immunization (AEFI) for CoronaVac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neurovascular adverse events, including thrombosis or ischaemic stroke after receiving CoronaVac have not previously been reported. Correspondingly, we reported three patients with an Acute Ischaemic Stroke (AIS) after the administration of CoronaVac in our hospital.

scholarly journals Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Carmen García-De-Vicuña ◽  
Manuel Díaz-Llopis ◽  
David Salom ◽  
Rosa Bou ◽  
Jesus Díaz-Cascajosa ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Side Effects ◽  
Body Surface ◽  
Case Series ◽  
Posterior Segment ◽  
Final Visit ◽  
Efficacy And Safety ◽  
The Mean ◽  
Prospective Case Series

Purpose. To assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis.Design. Multicenter, prospective case series.Methods. Thirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled. Patients aged 13–17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4–12 years received 24 mg/m2body surface.Results. Inflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P<0.001). The mean (SD) macular thickness at baseline was 304.54 (125.03) μand at the end of follow-up was 230.87 (31.12) μ(P<0.014). Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P<0.001). The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P<0.001). No significant side effects requiring discontinuation of therapy were observed.Conclusion. Adalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement.

scholarly journals Use of atypical antipsychotics by consultant psychiatrists working in forensic settings

2002 ◽  
Vol 26 (5) ◽  
pp. 172-174 ◽  
Author(s):  
Carol Paton ◽  
Jose A. Garcia ◽  
Deborah Brooke
Keyword(s):  
Side Effects ◽  
Serum Level ◽  
Atypical Antipsychotics ◽  
Response Rate ◽  
Postal Questionnaire ◽  
Clinical Implications ◽  
Forensic Patients ◽  
The Uk ◽  
Level Monitoring ◽  
Typical And Atypical Antipsychotics

AIMS AND METHODAtypical antipsychotics have less neurological side-effects than the older drugs but are only available as oral preparations. This may limit their use in forensic patients. We sent a postal questionnaire to all consultant psychiatrists working in forensic settings in the UK to determine their views.RESULTSThe response rate was 60%. Respondents tended to overestimate the benefits and underestimate the side-effects of the atypical antipsychotics. The majority often prescribed atypical antipsychotics and depots together. Psychoeducation and serum level monitoring were used to optimise/monitor compliance by 50%.CLINICAL IMPLICATIONSUsing atypical antipsychotics as monotherapy is problematic in forensic settings. The extent of polypharmacy means that patients may experience the side-effects of both typical and atypical antipsychotics. More could be done to facilitate and monitor compliance.

Sign in / Sign up

Export Citation Format

Share Document